<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OL</journal-id>
<journal-title-group>
<journal-title>Oncology Letters</journal-title></journal-title-group>
<issn pub-type="ppub">1792-1074</issn>
<issn pub-type="epub">1792-1082</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ol.2014.1912</article-id>
<article-id pub-id-type="publisher-id">ol-07-05-1341</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Identification of estrogen receptor proteins in breast cancer cells using matrix-assisted laser desorption/ionization time of flight mass spectrometry (Review)</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>HEGER</surname><given-names>ZBYNEK</given-names></name><xref rid="af1-ol-07-05-1341" ref-type="aff">1</xref><xref rid="af2-ol-07-05-1341" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>RODRIGO</surname><given-names>MIGUEL ANGEL MERLOS</given-names></name><xref rid="af1-ol-07-05-1341" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>KRIZKOVA</surname><given-names>SONA</given-names></name><xref rid="af2-ol-07-05-1341" ref-type="aff">2</xref><xref rid="af3-ol-07-05-1341" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author">
<name><surname>ZITKA</surname><given-names>ONDREJ</given-names></name><xref rid="af1-ol-07-05-1341" ref-type="aff">1</xref><xref rid="af2-ol-07-05-1341" ref-type="aff">2</xref><xref rid="af3-ol-07-05-1341" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author">
<name><surname>BEKLOVA</surname><given-names>MIROSLAVA</given-names></name><xref rid="af2-ol-07-05-1341" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>KIZEK</surname><given-names>RENE</given-names></name><xref rid="af2-ol-07-05-1341" ref-type="aff">2</xref><xref rid="af3-ol-07-05-1341" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author">
<name><surname>ADAM</surname><given-names>VOJTECH</given-names></name><xref rid="af2-ol-07-05-1341" ref-type="aff">2</xref><xref rid="af3-ol-07-05-1341" ref-type="aff">3</xref><xref ref-type="corresp" rid="c1-ol-07-05-1341"/></contrib></contrib-group>
<aff id="af1-ol-07-05-1341">
<label>1</label>Department of Veterinary Ecology and Environmental Protection, Faculty of Veterinary Hygiene and Ecology, University of Veterinary and Pharmaceutical Sciences Brno, Brno CZ-612 42, Czech Republic</aff>
<aff id="af2-ol-07-05-1341">
<label>2</label>Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, Brno CZ-613 00, Czech Republic</aff>
<aff id="af3-ol-07-05-1341">
<label>3</label>Central European Institute of Technology, Brno University of Technology, Brno CZ-616 00, Czech Republic</aff>
<author-notes>
<corresp id="c1-ol-07-05-1341">Correspondence to: Professor Vojtech Adam, Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, Brno CZ-613 00, Czech Republic, E-mail: <email>vojtech.adam@mendelu.cz</email></corresp></author-notes>
<pub-date pub-type="ppub">
<month>5</month>
<year>2014</year></pub-date>
<pub-date pub-type="epub">
<day>26</day>
<month>02</month>
<year>2014</year></pub-date>
<volume>7</volume>
<issue>5</issue>
<fpage>1341</fpage>
<lpage>1344</lpage>
<history>
<date date-type="received">
<day>29</day>
<month>06</month>
<year>2013</year></date>
<date date-type="accepted">
<day>06</day>
<month>12</month>
<year>2013</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2014, Spandidos Publications</copyright-statement>
<copyright-year>2014</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions>
<abstract>
<p>Estrogen receptors &#x0005B;ERs (subtypes &#x003B1; and &#x003B2;)&#x0005D;, classified as a nuclear receptor super family, are intracellular proteins with an important biological role as the transcription factors for estrogen target genes. For ER-induced transcription, an interaction must exist between ligand and coregulators. Coregulators may stimulate (coactivators) or inhibit (corepressors) transcription, following binding with a specific region of the gene, called the estrogen response element. Misbalanced activity of coregulators or higher ligand concentrations may cause increased cell proliferation, resulting in specific types of cancer. These are exhibited as overexpression of ER proteins. Breast cancer currently ranks first in the incidence and second in the mortality of cancer in females worldwide. In addition, 70&#x00025; of breast tumors are ER&#x003B1; positive and the importance of these proteins for diagnostic use is indisputable. Early diagnosis of the tumor and its classification has a large influence on the selection of appropriate therapy, as ER-positive tumors demonstrate a positive response to hormonal therapy. Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI TOF MS) has been hypothesized to have great potential, as it offers reliable, robust and efficient analysis methods for biomarker monitoring and identification. The present review discusses ER protein analysis by MALDI TOF MS, including the crucial step of protein separation.</p></abstract>
<kwd-group>
<kwd>matrix-assisted laser desorption/ionization time of flight</kwd>
<kwd>estrogen receptor</kwd>
<kwd>estrogen response element</kwd>
<kwd>cancer</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="other">
<title>1. Introduction</title>
<p>In 2011, breast cancer ranked first in the incidence and mortality of tumor diseases (<xref rid="b1-ol-07-05-1341" ref-type="bibr">1</xref>). Currently, it is the leading cause of cancer and continues to be the second most common cause of cancer mortality in females worldwide (<xref rid="b2-ol-07-05-1341" ref-type="bibr">2</xref>). In developed countries, the lower mortality rate is attributed to mammographic screening and advances in adjuvant therapy (<xref rid="b3-ol-07-05-1341" ref-type="bibr">3</xref>). The most commonly diagnosed breast cancer subtypes are luminal A and B tumors (<xref rid="b4-ol-07-05-1341" ref-type="bibr">4</xref>,<xref rid="b5-ol-07-05-1341" ref-type="bibr">5</xref>), together defined as the ER-positive (ER<sup>&#x0002B;</sup>) and progesterone receptor-positive (PgR<sup>&#x0002B;</sup>) tumors (<xref rid="b6-ol-07-05-1341" ref-type="bibr">6</xref>&#x02013;<xref rid="b8-ol-07-05-1341" ref-type="bibr">8</xref>). In total, &gt;70&#x00025; of breast cancers are ER<sup>&#x0002B;</sup> (<xref rid="b9-ol-07-05-1341" ref-type="bibr">9</xref>,<xref rid="b10-ol-07-05-1341" ref-type="bibr">10</xref>) and, thus, ERs remain the most informative biomarkers in specific subtypes of breast tumors (<xref rid="b3-ol-07-05-1341" ref-type="bibr">3</xref>,<xref rid="b11-ol-07-05-1341" ref-type="bibr">11</xref>). The ERs (subtypes &#x003B1; and &#x003B2;) are members of the nuclear receptor family of proteins modulating the expression of genes in response to ligand binding (<xref rid="b12-ol-07-05-1341" ref-type="bibr">12</xref>&#x02013;<xref rid="b14-ol-07-05-1341" ref-type="bibr">14</xref>). ER&#x003B1; expression occurs in bones, the uterus, mammary gland, liver and adipose tissue, whereas ER&#x003B2; is predominantly expressed in the ovary, mammary gland and intestinal tract. There is also expression of the two subtypes in the brain and cardiovascular system (<xref rid="b15-ol-07-05-1341" ref-type="bibr">15</xref>). ERs are located in the cell cytoplasm in a complex with the heat shock protein 90 chaperone, which dissociates following ligand binding (<xref rid="b16-ol-07-05-1341" ref-type="bibr">16</xref>). The ER-ligand complex is translocated into the nucleus, where it interacts with coregulators of transcription and binds to the estrogen response element (ERE) promoter region of a target gene and thereby activates mRNA transcription (<xref rid="b17-ol-07-05-1341" ref-type="bibr">17</xref>&#x02013;<xref rid="b19-ol-07-05-1341" ref-type="bibr">19</xref>). Identification of biomarkers using matrix-assisted laser desorption/ionization (MALDI) is currently of increasing significance and has contributed to rapid advances in metabolomics (<xref rid="b20-ol-07-05-1341" ref-type="bibr">20</xref>). MALDI may also be a powerful tool for investigation of biomarkers in biological systems, through the direct analysis of thin tissue sections (<xref rid="b21-ol-07-05-1341" ref-type="bibr">21</xref>), for example ERs in breast tissue. The present review aimed to summarize the evidence for the use of MALDI time of flight mass spectrometry (TOF MS) for the identification of ER proteins in breast cancer tissues.</p></sec>
<sec sec-type="other">
<title>2. ER proteins and tumor diseases</title>
<sec>
<title>ERs and cancer</title>
<p>Molecules acting as ER agonists generally exert a stimulatory effect on the proliferation of estrogen-sensitive breast carcinoma cells (<xref rid="b12-ol-07-05-1341" ref-type="bibr">12</xref>). In human breast cancer, ER<sup>&#x0002B;</sup> tumors exhibit an overexpression of ER&#x003B1; as a result of transcription from a promoter inactive in normal breast epithelium. In addition, behavior of ER&#x003B1; depends on the structure of the bound ligand &#x0005B;e.g. estradiol, the most active estrogen (<xref rid="b22-ol-07-05-1341" ref-type="bibr">22</xref>)&#x0005D; modulating the transcriptional activity of the estrogen responsive genes (<xref rid="b18-ol-07-05-1341" ref-type="bibr">18</xref>,<xref rid="b23-ol-07-05-1341" ref-type="bibr">23</xref>). ER&#x003B1;, as a main target in breast cancer, is influenced by a number of types of coregulator following ligand binding, including coactivators and corepressors (<xref rid="b24-ol-07-05-1341" ref-type="bibr">24</xref>). The balance between coregulators is crucial for regulation of gene transcription by ER&#x003B1; (<xref rid="b25-ol-07-05-1341" ref-type="bibr">25</xref>). Overexpression of coactivators, for example coactivator-associated arginine methyltransferase 1, may also increase the expression of ER&#x003B1; target genes involved in breast tumor cell differentiation and proliferation (<xref rid="b26-ol-07-05-1341" ref-type="bibr">26</xref>), including breast cancer (BRCA) 1 and BRCA2 genes (<xref rid="b27-ol-07-05-1341" ref-type="bibr">27</xref>). In addition, reduction of ER&#x003B1; spliced variant 46 (46 kDa) and 36 (36 kDa) mRNA levels have been observed in colon tumors (<xref rid="b28-ol-07-05-1341" ref-type="bibr">28</xref>) and overexpression of ER&#x003B1;36 has been observed in gastric (<xref rid="b29-ol-07-05-1341" ref-type="bibr">29</xref>) and endometrial cancers (<xref rid="b30-ol-07-05-1341" ref-type="bibr">30</xref>).</p></sec>
<sec>
<title>Role of ERs in diagnostics</title>
<p>It is well known that ER levels and emplacement of breast tumor metastasis are the fundamental and critical determinants of clinical outcome, with high prognostic values having the greatest impact on patient survival chances (<xref rid="b31-ol-07-05-1341" ref-type="bibr">31</xref>,<xref rid="b32-ol-07-05-1341" ref-type="bibr">32</xref>). The importance of ERs as breast carcinoma biomarkers is also due to the ability of the hormone receptor protein to provide detailed information about breast tumor subtype. ER<sup>&#x0002B;</sup> breast cancer types exhibit favorable responses to hormone therapy (<xref rid="b33-ol-07-05-1341" ref-type="bibr">33</xref>&#x02013;<xref rid="b35-ol-07-05-1341" ref-type="bibr">35</xref>), for example tamoxifen (<xref rid="b36-ol-07-05-1341" ref-type="bibr">36</xref>), or to aromatase inhibitors (<xref rid="b37-ol-07-05-1341" ref-type="bibr">37</xref>), designed to block aberrant signaling within oncogenic pathways (<xref rid="f1-ol-07-05-1341" ref-type="fig">Fig. 1</xref>). The use of neoadjuvant chemotherapy for the treatment of ER<sup>&#x0002B;</sup> tumors is associated with a major obstacle; chemoresistance (<xref rid="b38-ol-07-05-1341" ref-type="bibr">38</xref>,<xref rid="b39-ol-07-05-1341" ref-type="bibr">39</xref>). Hence, the identification of cancer subtypes using protein analysis is likely to enable the treatment effects of chemotherapy to be maximized (<xref rid="b40-ol-07-05-1341" ref-type="bibr">40</xref>). At present, the most utilized method for ER protein analysis in practice is immunohistochemistry (<xref rid="b41-ol-07-05-1341" ref-type="bibr">41</xref>&#x02013;<xref rid="b45-ol-07-05-1341" ref-type="bibr">45</xref>). Great potential has also been attributed to MALDI TOF MS offering reliable, robust and efficient analysis, renowned for its ease of operation and inexpensive matrixes required for sample preparation, as well as its derivative, surface-enhanced laser desorption/ionization spectrometry (<xref rid="b20-ol-07-05-1341" ref-type="bibr">20</xref>).</p></sec></sec>
<sec sec-type="other">
<title>3. MALDI TOF as a tool for analysis of ERs</title>
<p>MALDI TOF has been hypothesized to represent one of the most comprehensive and versatile tools for investigation of new biomarkers and protein analysis (<xref rid="b46-ol-07-05-1341" ref-type="bibr">46</xref>). A key element of the proteomic application of MALDI TOF is the separation of proteins from a sample using two-dimensional gel electrophoresis, prior to subsequent analysis by MS (<xref rid="f2-ol-07-05-1341" ref-type="fig">Fig. 2</xref>) (<xref rid="b47-ol-07-05-1341" ref-type="bibr">47</xref>,<xref rid="b48-ol-07-05-1341" ref-type="bibr">48</xref>). The MALDI TOF result, exhibited as protein peak spectra, may be quantitatively and statistically evaluated for determination of differential protein expression in response to a particular biological state (<xref rid="b49-ol-07-05-1341" ref-type="bibr">49</xref>). Nalvarte <italic>et al</italic> reported an approach for the isolation of ER&#x003B1; from MCF-7 cells based on the natural affinity of ER proteins towards the estrogen response element immobilized on a Sepharose column with subsequent two-dimensional electrophoresis, and identification using MALDI TOF mass spectrometry (<xref rid="b50-ol-07-05-1341" ref-type="bibr">50</xref>). This method provided a rapid method to identify ER&#x003B1; cofactor and transcription factor recruitment under various conditions. However, it has been hypothesized that the equivalent analysis of ER proteins in clinical samples is likely to be subject to extensive chemical noise that may invalidate results (<xref rid="b51-ol-07-05-1341" ref-type="bibr">51</xref>). The quantity and identity of biomarkers observed in tissue profiles are also influenced by a number of factors, including the volume of matrix solution used and the sites of laser shots application, used for ionization, which provides charge to molecules and thus enables proper mass detection, which facilitates rendering of the data into spatial distribution maps, or images for the many hundreds of ions measured in the mass spectra (<xref rid="b52-ol-07-05-1341" ref-type="bibr">52</xref>). A potential problem may be found also in the variability in sample preparation, leading to crystal heterogeneity, and thus to discrimination and suppression of certain signals. There are various approaches to minimize MALDI analysis, including the production of thin films by rapid drying of volatile solvents, or the use of electrospray with the ability to produce thin homogeneous films (<xref rid="b51-ol-07-05-1341" ref-type="bibr">51</xref>). The lack of further evidence associated with the diagnosis of breast cancer by MALDI TOF analysis of ERs highlights the issues associated with ER protein analysis in real biological samples. However, this method demonstrates excellent results for the visualization of protein expression (<xref rid="b46-ol-07-05-1341" ref-type="bibr">46</xref>,<xref rid="b53-ol-07-05-1341" ref-type="bibr">53</xref>), DNA methylation status (<xref rid="b54-ol-07-05-1341" ref-type="bibr">54</xref>), monitoring of ER interactions (<xref rid="b55-ol-07-05-1341" ref-type="bibr">55</xref>,<xref rid="b56-ol-07-05-1341" ref-type="bibr">56</xref>) and in searching for new biomarkers for breast cancer diagnosis (<xref rid="b57-ol-07-05-1341" ref-type="bibr">57</xref>,<xref rid="b58-ol-07-05-1341" ref-type="bibr">58</xref>).</p></sec>
<sec sec-type="other">
<title>4. Immunohistochemistry versus MALDI TOF</title>
<p>At present, the most commonly used method for differentiation of breast cancer subtypes is immunohistochemical classification, based on the level of expression of ERs and progesterone receptors (<xref rid="b41-ol-07-05-1341" ref-type="bibr">41</xref>,<xref rid="b42-ol-07-05-1341" ref-type="bibr">42</xref>). This method provides relatively accurate results (false negativity, 15.1&#x00025;), however, it can be time-consuming when analysis of a large number of samples is necessary, requiring sample staining, incubation, application of antibodies and visualization. By contrast, MALDI TOF MS may be useful for the analysis of large amounts of tissue samples. The greatest disadvantage of MALDI MS is the acquisition costs, however, this is balanced by reduced operating costs, reliability, robustness and efficiency. Additionally, ER isolation must be performed using two-dimensional gel electrophoresis (<xref rid="b47-ol-07-05-1341" ref-type="bibr">47</xref>) or a chromatographic system, in which several issues limit the isolation and proteomic analysis of ER complexes. The greatest of these is the low amount of endogenous ERs complexed with EREs, increasing the requirement for sensitivity of analytical methods used for isolation, and therefore it is necessary to find compromise between protein isolation efficiency and accuracy of the method utilized for its detection (<xref rid="b50-ol-07-05-1341" ref-type="bibr">50</xref>). However, MALDI may be useful for other applications, for example the monitoring of cancer gene expression (<xref rid="b53-ol-07-05-1341" ref-type="bibr">53</xref>,<xref rid="b59-ol-07-05-1341" ref-type="bibr">59</xref>).</p></sec>
<sec sec-type="other">
<title>5. Conclusions</title>
<p>ER proteins are important for diagnostics and classification of breast tumors subtypes. In particular, the need for identification of the cancer subtype is vital for selection of the appropriate treatment, and to predict the chemoresistance which is commonly noted in ER<sup>&#x0002B;</sup> tumors. At present, immunohistochemistry provides good results, however, this technique is laborious. Large diagnostic potential has been attributed to MALDI TOF MS but, due to the relatively recent development and high cost, the use of this application in clinical practice remains uncommon.</p></sec></body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This study was supported by grants from the Internal Grant Agency of the University of Veterinary and Pharmaceutical Sciences Brno (project 4/2013/FVHE) and MSMT (no. 6215712402).</p></ack>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term id="G1">ER</term>
<def>
<p>estrogen receptor</p></def></def-item>
<def-item>
<term id="G2">ER<sup>&#x0002B;</sup></term>
<def>
<p>estrogen receptor positive</p></def></def-item>
<def-item>
<term id="G3">PgR<sup>&#x0002B;</sup></term>
<def>
<p>progesteron receptor positive</p></def></def-item>
<def-item>
<term id="G4">ERE</term>
<def>
<p>estrogen response element</p></def></def-item>
<def-item>
<term id="G5">MALDI TOF</term>
<def>
<p>matrix-assisted laser desorption/ionization time of flight</p></def></def-item></def-list></glossary>
<ref-list>
<title>References</title>
<ref id="b1-ol-07-05-1341"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Center</surname><given-names>MM</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name></person-group><article-title>Global cancer statistics</article-title><source>CA Cancer J Clin</source><volume>61</volume><fpage>69</fpage><lpage>90</lpage><year>2011</year></element-citation></ref>
<ref id="b2-ol-07-05-1341"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Naishadham</surname><given-names>D</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2013</article-title><source>CA Cancer J Clin</source><volume>63</volume><fpage>11</fpage><lpage>30</lpage><year>2013</year></element-citation></ref>
<ref id="b3-ol-07-05-1341"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patani</surname><given-names>N</given-names></name><name><surname>Martin</surname><given-names>LA</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name></person-group><article-title>Biomarkers for the clinical management of breast cancer: international perspective</article-title><source>Int J Cancer</source><volume>133</volume><fpage>1</fpage><lpage>13</lpage><year>2013</year></element-citation></ref>
<ref id="b4-ol-07-05-1341"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carey</surname><given-names>LA</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Livasy</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study</article-title><source>JAMA</source><volume>295</volume><fpage>2492</fpage><lpage>2502</lpage><year>2006</year></element-citation></ref>
<ref id="b5-ol-07-05-1341"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>XR</given-names></name><name><surname>Chang-Claude</surname><given-names>J</given-names></name><name><surname>Goode</surname><given-names>EL</given-names></name><etal/></person-group><article-title>Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies</article-title><source>J Natl Cancer Inst</source><volume>103</volume><fpage>250</fpage><lpage>263</lpage><year>2011</year></element-citation></ref>
<ref id="b6-ol-07-05-1341"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muss</surname><given-names>HB</given-names></name></person-group><article-title>Coming of age: breast cancer in seniors</article-title><source>Oncologist</source><volume>16</volume><issue>Suppl 1</issue><fpage>S79</fpage><lpage>S87</lpage><year>2011</year></element-citation></ref>
<ref id="b7-ol-07-05-1341"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Sullivan-Halley</surname><given-names>J</given-names></name><etal/></person-group><article-title>Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women&#x02019;s contraceptive and reproductive experiences study</article-title><source>Cancer Res</source><volume>70</volume><fpage>575</fpage><lpage>587</lpage><year>2010</year></element-citation></ref>
<ref id="b8-ol-07-05-1341"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shubbar</surname><given-names>E</given-names></name><name><surname>Helou</surname><given-names>K</given-names></name><name><surname>Kov&#x000E1;cs</surname><given-names>A</given-names></name><etal/></person-group><article-title>High levels of &#x003B3;-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer</article-title><source>BMC Cancer</source><volume>13</volume><fpage>47</fpage><year>2013</year></element-citation></ref>
<ref id="b9-ol-07-05-1341"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name></person-group><article-title>MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications</article-title><source>Clin Transl Oncol</source><volume>15</volume><fpage>335</fpage><lpage>342</lpage><year>2013</year></element-citation></ref>
<ref id="b10-ol-07-05-1341"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ombra</surname><given-names>MN</given-names></name><name><surname>Di Santi</surname><given-names>A</given-names></name><name><surname>Abbondanza</surname><given-names>C</given-names></name><name><surname>Migliaccio</surname><given-names>A</given-names></name><name><surname>Avvedimento</surname><given-names>EV</given-names></name><name><surname>Perillo</surname><given-names>B</given-names></name></person-group><article-title>Retinoic acid impairs estrogen signaling in breast cancer cells by interfering with activation of LSD1 via PKA</article-title><source>Biochim Biophys Acta</source><volume>1829</volume><fpage>480</fpage><lpage>486</lpage><year>2013</year></element-citation></ref>
<ref id="b11-ol-07-05-1341"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasching</surname><given-names>PA</given-names></name><name><surname>Heusinger</surname><given-names>K</given-names></name><name><surname>Haeberle</surname><given-names>L</given-names></name><etal/></person-group><article-title>Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment</article-title><source>BMC Cancer</source><volume>11</volume><fpage>486</fpage><year>2011</year></element-citation></ref>
<ref id="b12-ol-07-05-1341"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharan</surname><given-names>S</given-names></name><name><surname>Nikhil</surname><given-names>K</given-names></name><name><surname>Roy</surname><given-names>P</given-names></name></person-group><article-title>Effects of low dose treatment of tributyltin on the regulation of estrogen receptor functions in MCF-7 cells</article-title><source>Toxicol Appl Pharmacol</source><volume>269</volume><fpage>176</fpage><lpage>186</lpage><year>2013</year></element-citation></ref>
<ref id="b13-ol-07-05-1341"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Wen</surname><given-names>H</given-names></name><etal/></person-group><article-title>The novel estrogen receptor GPER regulates the migration and invasion of ovarian cancer cells</article-title><source>Mol Cell Biochem</source><volume>378</volume><fpage>1</fpage><lpage>7</lpage><year>2013</year></element-citation></ref>
<ref id="b14-ol-07-05-1341"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>Y</given-names></name><name><surname>Chung</surname><given-names>KC</given-names></name></person-group><article-title>Zinc finger protein 131 inhibits estrogen signaling by suppressing estrogen receptor &#x003B1; homo-dimerization</article-title><source>Biochem Biophys Res Commun</source><volume>430</volume><fpage>400</fpage><lpage>405</lpage><year>2013</year></element-citation></ref>
<ref id="b15-ol-07-05-1341"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komm</surname><given-names>BS</given-names></name><name><surname>Mirkin</surname><given-names>S</given-names></name></person-group><article-title>Evolution of the tissue selective estrogen complex (TSEC)</article-title><source>J Cell Physiol</source><volume>228</volume><fpage>1423</fpage><lpage>1427</lpage><year>2013</year></element-citation></ref>
<ref id="b16-ol-07-05-1341"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Q</given-names></name><name><surname>Chang</surname><given-names>JT</given-names></name><name><surname>Geradts</surname><given-names>J</given-names></name><etal/></person-group><article-title>Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer</article-title><source>Breast Cancer Res</source><volume>14</volume><fpage>R62</fpage><year>2012</year></element-citation></ref>
<ref id="b17-ol-07-05-1341"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coughlan</surname><given-names>N</given-names></name><name><surname>Thillainadesan</surname><given-names>G</given-names></name><name><surname>Andrews</surname><given-names>J</given-names></name><name><surname>Isovic</surname><given-names>M</given-names></name><name><surname>Torchia</surname><given-names>J</given-names></name></person-group><article-title>&#x003B2;-Estradiol-dependent activation of the JAK/STAT pathway requires p/CIP and CARM1</article-title><source>Biochim Biophys Acta-Mol Cell Res</source><volume>1833</volume><fpage>1463</fpage><lpage>1475</lpage><year>2013</year></element-citation></ref>
<ref id="b18-ol-07-05-1341"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname><given-names>S</given-names></name><name><surname>Obiorah</surname><given-names>I</given-names></name><name><surname>Maximov</surname><given-names>PY</given-names></name><name><surname>Curpan</surname><given-names>R</given-names></name><name><surname>Jordan</surname><given-names>VC</given-names></name></person-group><article-title>Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells</article-title><source>Br J Pharmacol</source><volume>169</volume><fpage>167</fpage><lpage>178</lpage><year>2013</year></element-citation></ref>
<ref id="b19-ol-07-05-1341"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>ER</given-names></name></person-group><article-title>Integration of the extranuclear and nuclear actions of estrogen</article-title><source>Mol Endocrinol</source><volume>19</volume><fpage>1951</fpage><lpage>1959</lpage><year>2005</year></element-citation></ref>
<ref id="b20-ol-07-05-1341"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirman</surname><given-names>DA</given-names></name><name><surname>Efuet</surname><given-names>E</given-names></name><name><surname>Ding</surname><given-names>XP</given-names></name><etal/></person-group><article-title>Changes in cancer cell metabolism revealed by direct sample analysis with MALDI mass spectrometry</article-title><source>PLoS One</source><volume>8</volume><fpage>e61379</fpage><year>2013</year></element-citation></ref>
<ref id="b21-ol-07-05-1341"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornett</surname><given-names>DS</given-names></name><name><surname>Reyzer</surname><given-names>ML</given-names></name><name><surname>Chaurand</surname><given-names>P</given-names></name><name><surname>Caprioli</surname><given-names>RM</given-names></name></person-group><article-title>MALDI imaging mass spectrometry: molecular snapshots of biochemical systems</article-title><source>Nat Methods</source><volume>4</volume><fpage>828</fpage><lpage>833</lpage><year>2007</year></element-citation></ref>
<ref id="b22-ol-07-05-1341"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HS</given-names></name><name><surname>Wu</surname><given-names>HM</given-names></name><name><surname>Cheng</surname><given-names>BH</given-names></name><etal/></person-group><article-title>Functional analyses of endometriosis-related polymorphisms in the estrogen synthesis and metabolism-related genes</article-title><source>PLoS One</source><volume>7</volume><fpage>e47374</fpage><year>2012</year></element-citation></ref>
<ref id="b23-ol-07-05-1341"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srinivasan</surname><given-names>S</given-names></name><name><surname>Nwachukwu</surname><given-names>JC</given-names></name><name><surname>Parent</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Ligand-binding dynamics rewire cellular signaling via estrogen receptor-&#x003B1;</article-title><source>Nat Chem Biol</source><volume>9</volume><fpage>326</fpage><lpage>332</lpage><year>2013</year></element-citation></ref>
<ref id="b24-ol-07-05-1341"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aust</surname><given-names>S</given-names></name><name><surname>Horak</surname><given-names>P</given-names></name><name><surname>Pils</surname><given-names>D</given-names></name><etal/></person-group><article-title>The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer</article-title><source>BMC Cancer</source><volume>13</volume><fpage>115</fpage><year>2013</year></element-citation></ref>
<ref id="b25-ol-07-05-1341"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borjesson</surname><given-names>AE</given-names></name><name><surname>Farman</surname><given-names>HH</given-names></name><name><surname>Engdahl</surname><given-names>C</given-names></name><etal/></person-group><article-title>The role of activation functions 1 and 2 of estrogen receptor-&#x003B1; for the effects of estradiol and selective estrogen receptor modulators in male mice</article-title><source>J Bone Miner Res</source><volume>28</volume><fpage>1117</fpage><lpage>1126</lpage><year>2013</year></element-citation></ref>
<ref id="b26-ol-07-05-1341"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>JC</given-names></name><name><surname>Bedford</surname><given-names>MT</given-names></name><etal/></person-group><article-title>A TR-FRET-based functional assay for screening activators of CARM1</article-title><source>Chembiochem</source><volume>14</volume><fpage>827</fpage><lpage>835</lpage><year>2013</year></element-citation></ref>
<ref id="b27-ol-07-05-1341"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meric-Bernstam</surname><given-names>F</given-names></name><name><surname>Gutierrez-Barrera</surname><given-names>AM</given-names></name><name><surname>Litton</surname><given-names>J</given-names></name><etal/></person-group><article-title>Genotype in BRCA-associated breast cancers</article-title><source>Breast J</source><volume>19</volume><fpage>87</fpage><lpage>91</lpage><year>2013</year></element-citation></ref>
<ref id="b28-ol-07-05-1341"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Teng</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Transcriptional analysis of estrogen receptor alpha variant mRNAs in colorectal cancers and their matched normal colorectal tissues</article-title><source>J Steroid Biochem Mol Biol</source><volume>112</volume><fpage>20</fpage><lpage>24</lpage><year>2008</year></element-citation></ref>
<ref id="b29-ol-07-05-1341"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>R</given-names></name><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name></person-group><article-title>Expression of ER&#x003B1;36 in gastric cancer samples and their matched normal tissues</article-title><source>Oncol Lett</source><volume>3</volume><fpage>172</fpage><lpage>175</lpage><year>2012</year></element-citation></ref>
<ref id="b30-ol-07-05-1341"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>BB</given-names></name><name><surname>Lin</surname><given-names>SL</given-names></name><name><surname>Yan</surname><given-names>LY</given-names></name><name><surname>Wang</surname><given-names>ZY</given-names></name><name><surname>Sun</surname><given-names>QY</given-names></name><name><surname>Qiao</surname><given-names>J</given-names></name></person-group><article-title>ER-&#x003B1;36, a novel variant of estrogen receptor &#x003B1;, is involved in EGFR-related carcinogenesis in endometrial cancer</article-title><source>Am J Obstet Gynecol</source><volume>205</volume><fpage>227.e1</fpage><lpage>e6</lpage><year>2011</year></element-citation></ref>
<ref id="b31-ol-07-05-1341"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kammerer</surname><given-names>M</given-names></name><name><surname>Gutzwiller</surname><given-names>S</given-names></name><name><surname>Stauffer</surname><given-names>D</given-names></name><name><surname>Delhon</surname><given-names>I</given-names></name><name><surname>Seltenmeyer</surname><given-names>Y</given-names></name><name><surname>Fournier</surname><given-names>B</given-names></name></person-group><article-title>Estrogen receptor &#x003B1; (ER&#x003B1;) and estrogen related receptor &#x003B1; (ERR&#x003B1;) are both transcriptional regulators of the Runx2-I isoform</article-title><source>Mol Cell Endocrinol</source><volume>369</volume><fpage>150</fpage><lpage>160</lpage><year>2013</year></element-citation></ref>
<ref id="b32-ol-07-05-1341"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamucci</surname><given-names>T</given-names></name><name><surname>Vaccaro</surname><given-names>A</given-names></name><name><surname>Ciancola</surname><given-names>F</given-names></name><etal/></person-group><article-title>Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis</article-title><source>J Cancer Res Clin Oncol</source><volume>139</volume><fpage>853</fpage><lpage>860</lpage><year>2013</year></element-citation></ref>
<ref id="b33-ol-07-05-1341"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Althuis</surname><given-names>MD</given-names></name><name><surname>Fergenbaum</surname><given-names>JH</given-names></name><name><surname>Garcia-Closas</surname><given-names>M</given-names></name><name><surname>Brinton</surname><given-names>LA</given-names></name><name><surname>Madigan</surname><given-names>MP</given-names></name><name><surname>Sherman</surname><given-names>ME</given-names></name></person-group><article-title>Etiology of hormone receptor-defined breast cancer: a systematic review of the literature</article-title><source>Cancer Epidemiol Biomarkers Prev</source><volume>13</volume><fpage>1558</fpage><lpage>1568</lpage><year>2004</year></element-citation></ref>
<ref id="b34-ol-07-05-1341"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thrane</surname><given-names>S</given-names></name><name><surname>Lykkesfeldt</surname><given-names>AE</given-names></name><name><surname>Larsen</surname><given-names>MS</given-names></name><name><surname>Sorensen</surname><given-names>BS</given-names></name><name><surname>Yde</surname><given-names>CW</given-names></name></person-group><article-title>Estrogen receptor &#x003B1; is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling</article-title><source>Breast Cancer Res Treat</source><volume>139</volume><fpage>71</fpage><lpage>80</lpage><year>2013</year></element-citation></ref>
<ref id="b35-ol-07-05-1341"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foulkes</surname><given-names>WD</given-names></name><name><surname>Smith</surname><given-names>IE</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name></person-group><article-title>Triple-negative breast cancer</article-title><source>N Engl J Med</source><volume>363</volume><fpage>1938</fpage><lpage>1948</lpage><year>2010</year></element-citation></ref>
<ref id="b36-ol-07-05-1341"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez-Ardila</surname><given-names>DE</given-names></name><name><surname>Helmijr</surname><given-names>JC</given-names></name><name><surname>Look</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen</article-title><source>Breast Cancer Res Treat</source><volume>139</volume><fpage>39</fpage><lpage>49</lpage><year>2013</year></element-citation></ref>
<ref id="b37-ol-07-05-1341"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiscox</surname><given-names>S</given-names></name><name><surname>Davies</surname><given-names>EL</given-names></name><name><surname>Barrett-Lee</surname><given-names>P</given-names></name></person-group><article-title>Aromatase inhibitors in breast cancer</article-title><source>Maturitas</source><volume>63</volume><fpage>275</fpage><lpage>279</lpage><year>2009</year></element-citation></ref>
<ref id="b38-ol-07-05-1341"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodgkinson</surname><given-names>VC</given-names></name><name><surname>Agarwal</surname><given-names>V</given-names></name><name><surname>El Fadl</surname><given-names>D</given-names></name><etal/></person-group><article-title>Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer</article-title><source>J Proteomics</source><volume>75</volume><fpage>2745</fpage><lpage>2752</lpage><year>2012</year></element-citation></ref>
<ref id="b39-ol-07-05-1341"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SI</given-names></name><name><surname>Sohn</surname><given-names>J</given-names></name><name><surname>Koo</surname><given-names>JS</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>BW</given-names></name></person-group><article-title>Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer</article-title><source>Oncology</source><volume>79</volume><fpage>324</fpage><lpage>330</lpage><year>2010</year></element-citation></ref>
<ref id="b40-ol-07-05-1341"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddock</surname><given-names>CL</given-names></name><name><surname>Holtz</surname><given-names>B</given-names></name><name><surname>Senzer</surname><given-names>N</given-names></name><name><surname>Nemunaitis</surname><given-names>J</given-names></name></person-group><article-title>Applications of HPLC-MALDI-TOF MS/MS phosphoproteomic analysis in oncological clinical diagnostics</article-title><source>Curr Proteomics</source><volume>8</volume><fpage>153</fpage><lpage>167</lpage><year>2011</year></element-citation></ref>
<ref id="b41-ol-07-05-1341"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tangjitgamol</surname><given-names>S</given-names></name><name><surname>Tanvanich</surname><given-names>S</given-names></name><name><surname>Srijaipracharoen</surname><given-names>S</given-names></name><name><surname>Manusirivithaya</surname><given-names>S</given-names></name></person-group><article-title>Expression of estrogen receptor, progesterone receptor, and Her-2/neu in primary and extra-corporeal endometrial cancer</article-title><source>Histol Histopathol</source><volume>28</volume><fpage>787</fpage><lpage>794</lpage><year>2013</year></element-citation></ref>
<ref id="b42-ol-07-05-1341"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alkner</surname><given-names>S</given-names></name><name><surname>Bendahl</surname><given-names>PO</given-names></name><name><surname>Grabau</surname><given-names>D</given-names></name><etal/></person-group><article-title>The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor</article-title><source>Ann Oncol</source><volume>24</volume><fpage>1244</fpage><lpage>1252</lpage><year>2013</year></element-citation></ref>
<ref id="b43-ol-07-05-1341"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seferina</surname><given-names>SC</given-names></name><name><surname>Nap</surname><given-names>M</given-names></name><name><surname>van den Berkmortel</surname><given-names>F</given-names></name><name><surname>Wals</surname><given-names>J</given-names></name><name><surname>Voogd</surname><given-names>AC</given-names></name><name><surname>Tjan-Heijnen</surname><given-names>VC</given-names></name></person-group><article-title>Reliability of receptor assessment on core needle biopsy in breast cancer patients</article-title><source>Tumour Biol</source><volume>34</volume><fpage>987</fpage><lpage>994</lpage><year>2013</year></element-citation></ref>
<ref id="b44-ol-07-05-1341"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wik</surname><given-names>E</given-names></name><name><surname>R&#x000E6;der</surname><given-names>MB</given-names></name><name><surname>Krakstad</surname><given-names>C</given-names></name><etal/></person-group><article-title>Lack of estrogen receptor-&#x003B1; is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma</article-title><source>Clin Cancer Res</source><volume>19</volume><fpage>1094</fpage><lpage>1105</lpage><year>2013</year></element-citation></ref>
<ref id="b45-ol-07-05-1341"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinsella</surname><given-names>MD</given-names></name><name><surname>Birdsong</surname><given-names>GG</given-names></name><name><surname>Siddiqui</surname><given-names>MT</given-names></name><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Hanley</surname><given-names>KZ</given-names></name></person-group><article-title>Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples</article-title><source>Diagn Cytopathol</source><volume>41</volume><fpage>192</fpage><lpage>198</lpage><year>2013</year></element-citation></ref>
<ref id="b46-ol-07-05-1341"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sang</surname><given-names>QX</given-names></name><name><surname>Man</surname><given-names>YG</given-names></name><name><surname>Sung</surname><given-names>YM</given-names></name><etal/></person-group><article-title>Non-receptor tyrosine kinase 2 reaches its lowest expression levels in human breast cancer during regional nodal metastasis</article-title><source>Clin Exp Metastasis</source><volume>29</volume><fpage>143</fpage><lpage>153</lpage><year>2012</year></element-citation></ref>
<ref id="b47-ol-07-05-1341"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Histopathological and proteomic analysis of hepatic tissue from adult male zebrafish exposed to 17&#x003B2;-estradiol</article-title><source>Environ Toxicol Pharmacol</source><volume>29</volume><fpage>91</fpage><lpage>95</lpage><year>2010</year></element-citation></ref>
<ref id="b48-ol-07-05-1341"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietrowska</surname><given-names>M</given-names></name><name><surname>Marczak</surname><given-names>L</given-names></name><name><surname>Polanska</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer</article-title><source>J Transl Med</source><volume>7</volume><fpage>60</fpage><year>2009</year></element-citation></ref>
<ref id="b49-ol-07-05-1341"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouchal</surname><given-names>P</given-names></name><name><surname>Dvorakova</surname><given-names>M</given-names></name><name><surname>Scherl</surname><given-names>A</given-names></name><name><surname>Garbis</surname><given-names>SD</given-names></name><name><surname>Nenutil</surname><given-names>R</given-names></name><name><surname>Vojtesek</surname><given-names>B</given-names></name></person-group><article-title>Intact protein profiling in breast cancer biomarker discovery: protein identification issue and the solutions based on 3D protein separation, bottom-up and top-down mass spectrometry</article-title><source>Proteomics</source><volume>13</volume><fpage>1053</fpage><lpage>1058</lpage><year>2013</year></element-citation></ref>
<ref id="b50-ol-07-05-1341"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nalvarte</surname><given-names>I</given-names></name><name><surname>Schwend</surname><given-names>T</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name></person-group><article-title>Proteomics analysis of the estrogen receptor alpha receptosome</article-title><source>Mol Cell Proteomics</source><volume>9</volume><fpage>1411</fpage><lpage>1422</lpage><year>2010</year></element-citation></ref>
<ref id="b51-ol-07-05-1341"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atsriku</surname><given-names>C</given-names></name><name><surname>Benz</surname><given-names>CC</given-names></name><name><surname>Scott</surname><given-names>GK</given-names></name><name><surname>Gibson</surname><given-names>BW</given-names></name><name><surname>Baldwin</surname><given-names>MA</given-names></name></person-group><article-title>Quantification of cysteine oxidation in human estrogen receptor by mass spectrometry</article-title><source>Anal Chem</source><volume>79</volume><fpage>3083</fpage><lpage>3090</lpage><year>2007</year></element-citation></ref>
<ref id="b52-ol-07-05-1341"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornett</surname><given-names>DS</given-names></name><name><surname>Mobley</surname><given-names>JA</given-names></name><name><surname>Dias</surname><given-names>EC</given-names></name><etal/></person-group><article-title>A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer</article-title><source>Mol Cell Proteomics</source><volume>5</volume><fpage>1975</fpage><lpage>1983</lpage><year>2006</year></element-citation></ref>
<ref id="b53-ol-07-05-1341"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabbage</surname><given-names>M</given-names></name><name><surname>Trimeche</surname><given-names>M</given-names></name><name><surname>Bergaoui</surname><given-names>S</given-names></name><etal/></person-group><article-title>Calreticulin expression in infiltrating ductal breast carcinomas: relationships with disease progression and humoral immune responses</article-title><source>Tumour Biol</source><volume>34</volume><fpage>1177</fpage><lpage>1188</lpage><year>2013</year></element-citation></ref>
<ref id="b54-ol-07-05-1341"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castilla</surname><given-names>M&#x000C1;</given-names></name><name><surname>Diaz-Martin</surname><given-names>J</given-names></name><name><surname>Sarri&#x000F3;</surname><given-names>D</given-names></name><etal/></person-group><article-title>MicroRNA-200 family modulation in distinct breast cancer phenotypes</article-title><source>PLoS One</source><volume>7</volume><fpage>e47709</fpage><year>2012</year></element-citation></ref>
<ref id="b55-ol-07-05-1341"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paramanik</surname><given-names>V</given-names></name><name><surname>Thakur</surname><given-names>MK</given-names></name></person-group><article-title>Estrogen receptor &#x003B2; and its domains interact with casein kinase 2, phosphokinase C, and N-myristoylation sites of mitochondrial and nuclear proteins in mouse brain</article-title><source>J Biol Chem</source><volume>287</volume><fpage>22305</fpage><lpage>22316</lpage><year>2012</year></element-citation></ref>
<ref id="b56-ol-07-05-1341"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bovet</surname><given-names>C</given-names></name><name><surname>Plet</surname><given-names>B</given-names></name><name><surname>Ruff</surname><given-names>M</given-names></name><etal/></person-group><article-title>Towards high-throughput identification of endocrine disrupting compounds with mass spectrometry</article-title><source>Toxicol In Vitro</source><volume>23</volume><fpage>704</fpage><lpage>709</lpage><year>2009</year></element-citation></ref>
<ref id="b57-ol-07-05-1341"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collodoro</surname><given-names>M</given-names></name><name><surname>Lemaire</surname><given-names>P</given-names></name><name><surname>Eppe</surname><given-names>G</given-names></name><etal/></person-group><article-title>Identification and quantification of concentration-dependent biomarkers in MCF-7/BOS cells exposed to 17&#x003B2;-estradiol by 2-D DIGE and label-free proteomics</article-title><source>J Proteomics</source><volume>75</volume><fpage>4555</fpage><lpage>4569</lpage><year>2012</year></element-citation></ref>
<ref id="b58-ol-07-05-1341"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>TC</given-names></name><name><surname>Chou</surname><given-names>HC</given-names></name><name><surname>Chen</surname><given-names>YW</given-names></name><etal/></person-group><article-title>Secretomic and proteomic analysis of potential breast cancer markers by two-dimensional differential gel electrophoresis</article-title><source>J Proteome Res</source><volume>9</volume><fpage>1302</fpage><lpage>1322</lpage><year>2010</year></element-citation></ref>
<ref id="b59-ol-07-05-1341"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obazee</surname><given-names>O</given-names></name><name><surname>Justenhoven</surname><given-names>C</given-names></name><name><surname>Winter</surname><given-names>S</given-names></name><etal/></person-group><article-title>Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant</article-title><source>Breast Cancer Res Treat</source><volume>138</volume><fpage>543</fpage><lpage>548</lpage><year>2013</year></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-ol-07-05-1341" position="float">
<label>Figure 1</label>
<caption>
<p>Schematic representation of hormone treatment action in ER-positive breast cancer cells. E2, estradiol; Tam, tamoxifen; ER, estrogen receptor; ERE, estrogen response element.</p></caption>
<graphic xlink:href="OL-07-05-1341-g00.gif"/></fig>
<fig id="f2-ol-07-05-1341" position="float">
<label>Figure 2</label>
<caption>
<p>Schematic representation of protein identification in cancer cells by MALDI TOF MS. MALDI TOF MS, matrix-assisted laser desorption/ionization time of flight mass spectrometry.</p></caption>
<graphic xlink:href="OL-07-05-1341-g01.gif"/></fig></floats-group></article>
